Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what highlights there are to look forward to in the multiple myeloma field at ASH 2020. Immunotherapy will be the leading topic for myeloma, he says, with many presentations and sessions surrounding CAR-T cells, novel bispecific antibodies, and antibody-drug conjugates. He is also looking forward to seeing the results of allogeneic CAR T-cell studies in myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.